Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Leukemia. 2018 Feb 23;32(6):1370–1379. doi: 10.1038/s41375-018-0039-7

Table 5.

Exact levels of minimal residual disease in patients with discordant and concordantly not in remission end of Induction bone marrows, median (interquartile range)

M1/MRD≥5% M2/MRD≥5% p-value
B-precursor, overall 8.2 (6.2–14.4) 14.6 (7.1–25.9) 0.02
B-precursor, SR 7.7 (6.6–12.6) 8.3 (6.3–12.4) 0.89
B-precursor, HR 8.6 (6.1–18.1) 16 (9.0–27.3) 0.02
T-precursor, overall 9.7 (7.1–13.6) 21 (14.1–31.3) 0.02

HR – high risk; MRD – minimal residual disease; SR – standard risk